Lymphoproliferative Disorders

This is a group of diseases where the body makes too many lymphocytes, a type of white blood cell. Lymphocytes help fight infections. When they grow too much, it can cause problems like enlarged lymph nodes, swollen spleen, or make you more susceptible to infections. It's a broad category, and the specific type depends on the cause and other factors.

Condition

What people with Lymphoproliferative Disorders report

Every report comes from a Lived member, sent anonymously.

Have you had Stem Cell Transplant for Lymphoproliferative Disorders?

NameHow it went

About Lymphoproliferative Disorders

What It Is

Lymphoproliferative disorders are a group of conditions in which lymphocytes, the white blood cells of the immune system, multiply far more than they should. The extra cells can build up in lymph nodes, the spleen, the liver, the bone marrow and other organs. Some of these disorders behave like cancer and are treated like it; others are mainly problems of immune control. Because the label covers very different diseases, the specific type matters more than the umbrella name. In practice, the label usually points to one of three kinds of disease. Cancers of lymphocytes, such as lymphomas and chronic lymphocytic leukemia (CLL), belong to the group, and each is diagnosed and treated as a specific blood cancer. Post-transplant lymphoproliferative disorder (PTLD) can develop in people taking long-term anti-rejection medicines after an organ or stem cell transplant. The third kind is a set of rare, mostly inherited disorders of immune control. One of these is autoimmune lymphoproliferative syndrome (ALPS), which enlarges the lymph nodes, liver and spleen and often causes the immune system to attack blood cells. Because lymphomas and CLL are each managed as their own cancer, the rest of this page focuses on PTLD and the immune-control disorders. Another rare inherited example is X-linked lymphoproliferative disease (XLP), also called Duncan disease or Purtilo syndrome, which occurs almost only in boys and men. People with XLP cannot properly control their immune response to the Epstein-Barr virus (EBV), the common virus that causes mononucleosis (mono). Instead of settling down after infection, the immune system can spiral into hemophagocytic lymphohistiocytosis (HLH), a life-threatening reaction that causes fever, damages the liver and destroys blood-forming cells in the bone marrow. People with XLP may also have low or abnormal antibody levels, which leads to repeated infections, and about one-third develop lymphoma, a cancer of immune cells. XLP has two genetic forms, and this lymphoma risk has been seen in XLP1, the classic form, but not in XLP2.

Causes & Risk Factors

The causes depend on the type. XLP is genetic. It is caused by a change in one of two genes on the X chromosome, known as SH2D1A (causing XLP1, the classic form) and XIAP (causing XLP2). Because males have one X chromosome, a single altered copy causes the disease, while females with one altered copy usually have no symptoms, though rare exceptions occur. A mother who carries the change has a chance of passing it to each son; fathers cannot pass it to their sons. XLP1 is estimated to affect about 1 in a million males, and XLP2 is rarer still. EBV infection is the usual trigger for the most dangerous complications, but HLH can also occur without it, particularly in XLP2. PTLD is driven by long-term suppression of the immune system after a transplant. The highest-risk situation is a recipient who has never had EBV receiving an organ from a donor who has; children are more often in that position. Risk also rises with intestinal, lung and multiorgan transplants and with stronger or longer immunosuppression. ALPS is usually inherited and comes from changes in genes that normally tell surplus lymphocytes to die off.

How It's Diagnosed

Diagnosis starts with the clinical picture: enlarged lymph nodes, spleen or liver, persistent fever, unexplained low blood counts or an unusually severe illness after EBV infection. Blood tests check blood counts, antibody levels and the amount of EBV in the blood (an EBV viral load measured by a test called PCR). Imaging, often a PET/CT scan (a combined scan that maps both body structures and unusually active tissue), shows where enlarged or active tissue is and helps choose a place to sample. For PTLD and lymphoma-like growths, a tissue biopsy is usually what settles the diagnosis. A pathologist examines the cells to decide which type is present, whether EBV is involved and how aggressive it looks, and that classification guides treatment. For XLP, genetic testing is the gold standard. Specialized blood tests that check whether the immune protein made by the XLP1 gene is missing can screen quickly, but reading the gene itself confirms the diagnosis. Doctors consider XLP in boys with HLH, severe or fatal EBV illness, low antibody levels or lymphoma, especially with a family history of affected males on the mother's side. Once a family's gene change is known, relatives can be tested, including brothers who have not yet had symptoms.

Treatment Options

Treatment is matched to the specific disorder, so options differ widely. For XLP, a stem cell transplant (also called a bone marrow transplant) is currently the only treatment that can cure the disease, because it replaces the faulty immune system with a donor's. In published case series, people who received a transplant survived more often than those who did not. It carries serious risks, including graft-versus-host disease, in which donor cells attack the body, so outcomes are best with a well-matched donor. Whether to transplant a boy who has not yet had symptoms is still debated, although some studies suggest better results when transplant happens before complications. Before or alongside transplant, care focuses on preventing and controlling complications: regular checks of EBV levels, immunoglobulin replacement (antibodies given by infusion) to prevent infections when antibody levels are low, and rituximab (Rituxan), an antibody medicine that clears B cells (the lymphocytes that make antibodies and that EBV infects), though for that reason it can leave antibody levels low for a long time. HLH is treated urgently in specialist centers with medicines that suppress the overactive immune response, and lymphoma is treated with standard chemotherapy, usually followed by transplant. For PTLD after an organ transplant, the first step is usually to lower anti-rejection medicines so the person's own immune system can fight the abnormal cells. This works on its own for many early or less aggressive forms but rarely for aggressive ones, and it must be balanced against the risk of rejecting the transplanted organ, so the transplant and cancer teams decide together. If that is not enough, rituximab comes next for the common B-cell type, followed by chemotherapy combined with rituximab for disease that persists or is high risk from the start. For ALPS, treatment aims to control the immune system's attacks on blood cells and, when they cause problems, the enlarged lymph nodes and spleen. Corticosteroids have long been used for this. Sirolimus, an immune-suppressing medicine that reduces lymphocyte overgrowth, is now a key option for people who need long-term treatment, partly because it lets them rely less on steroids. Its dose is adjusted using regular blood tests of the drug level. Because these medicines dampen the immune system, care also includes protecting against infections. Stem cell transplant is generally not recommended for ALPS.

What to Expect

The outlook varies enormously by type. Without treatment, most people with XLP survive only into childhood, mainly because of HLH. Transplant has changed that picture for many families, though transplant recovery involves a long period of close monitoring for infection and graft-versus-host disease. Some people with XLP who are not transplanted live into adulthood with supportive care, but they remain at risk of late complications, so lifelong specialist follow-up is needed either way. PTLD can range from a mild, slow problem found by chance to an aggressive lymphoma. Many people respond to treatment. Follow-up is usually most frequent in the first two years, typically every few months, and includes examinations, blood tests including EBV levels and scans. The transplant team will also reassess anti-rejection medicines over time to balance protecting the organ against keeping PTLD away. People with the classic form of ALPS generally have a near-normal lifespan. Their risk of lymphoma is much higher than average, however, so they need ongoing specialist follow-up both to manage autoimmune problems and to watch for lymphoma. Because several of these disorders are inherited, a diagnosis often affects the wider family. Genetic counseling can explain who else may carry the gene change and what testing or family planning options exist.

When to Seek Help

Arrange an evaluation for lymph nodes that stay enlarged, persistent fever without a clear cause, repeated or unusually severe infections, or a family history of boys with severe mono, HLH or lymphoma. If you or your son has XLP or a family gene change, contact the care team promptly about any fever or mono-like illness, since EBV infection is when HLH usually begins. If you have had a transplant, tell your transplant team about persistent fever, drenching night sweats, unexplained weight loss or new swollen lymph nodes, which can be early signs of PTLD. A transplant recipient who has a seizure or suddenly becomes confused needs emergency care right away (call 911). A new severe or persistent headache needs a same-day call to the transplant team for urgent evaluation. Both can be signs of PTLD affecting the brain, and a seizure or confusion can also come from a brain infection or medicine toxicity.

Questions to Ask Your Doctor

  1. 1.Which specific type of lymphoproliferative disorder is this, and how does that change treatment and outlook?
  2. 2.What did the biopsy or genetic testing show, and do we need any further tests?
  3. 3.Is a stem cell transplant an option, and how would we weigh its risks against waiting?
  4. 4.Should other family members be offered genetic testing or counseling?
  5. 5.What symptoms should prompt a call to you, and how will we monitor between visits?

Last reviewed • Oct 2026

Educational content, not medical advice.